Friday, January 2, 2026 1/2/2026

Elucidating the role of gut microbiota in colitis-associated colorectal cancer

Award Number: R01CA276173
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 01/01/2023
PERIOD OF PERFORMANCE END DATE: 12/31/2027

Group Awards By:

View Award Description

Elucidating the role of gut microbiota in colitis-associated colorectal cancer - Abstract Patients with ulcerative colitis (UC), an inflammatory bowel disease (IBD), have an increased risk of developing colitis-associated colorectal cancer (CAC). Human gut microbiome composition has recently been associated with a wide array of diseases, including IBD and colorectal cancer. Studies have shown that gut microbiota could influence colon epithelium to initiate or promote colorectal cancer development directly or indirectly. However, little is known on the structure and function of the microbiota in CAC and how they implicate the development of CAC at the molecular level. In this study, we will investigate the role of microbiota in the development of CAC, as well as the molecular events underlying the interplay of microbiota and host response. The project builds upon our previous studies in examining the genomic instabilities and proteome alterations in the colon epithelium during the pathogenesis of IBD-CAC, and will focus on the mechanistic and functional involvement of the microbiome and their components in the modulation (by protective bacteria) or activation (by tumorigenic bacteria) of CAC development. Specifically, we will investigate the implication of mucosa- associated microbiota in CAC by an integrated approach using three model systems, including clinical specimens (Aim 1), in vitro microbial cultivation and organoid models (Aim 2), and in vivo mouse model (Aim 3). Our integrative, state-of-the-art approach will characterize the composition, functional genes and pathways of the microbiome implicated in CAC, and the impact of microbiota on colon mucosa. By studying the gut microbiota and its interplay with the colon host using novel approaches and cutting-edge technology, our study has significant translational potential that could lead to establishing the gut microbiome as predictors of CAC risk and aid in developing approaches for CAC prevention and detection in IBD patients.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $554,291 )
2026	2026	BAYLOR COLLEGE OF MEDICINE	1 BAYLOR PLZ	HOUSTON	TX	77030	HARRIS	USA	Cancer Biology Research	000	4	12/18/2025	NON-COMPETING CONTINUATION	$554,291
														Subtotal = $554,291

Issue Date FY: 2025 ( Subtotal = $615,878 )
2025	2025	BAYLOR COLLEGE OF MEDICINE	1 BAYLOR PLZ	HOUSTON	TX	77030	HARRIS	USA	Cancer Biology Research	001	3	6/10/2025	NON-COMPETING CONTINUATION	$61,587
2025	2025	BAYLOR COLLEGE OF MEDICINE	1 BAYLOR PLZ	HOUSTON	TX	77030	HARRIS	USA	Cancer Biology Research	000	3	12/6/2024	NON-COMPETING CONTINUATION	$554,291
														Subtotal = $615,878

Issue Date FY: 2024 ( Subtotal = $585,084 )
2024	2024	BAYLOR COLLEGE OF MEDICINE	1 BAYLOR PLZ	HOUSTON	TX	77030	HARRIS	USA	Cancer Biology Research	001	2	4/15/2024	NON-COMPETING CONTINUATION	$30,793
2024	2024	BAYLOR COLLEGE OF MEDICINE	1 BAYLOR PLZ	HOUSTON	TX	77030	HARRIS	USA	Cancer Biology Research	000	2	1/5/2024	NON-COMPETING CONTINUATION	$554,291
														Subtotal = $585,084

Issue Date FY: 2023 ( Subtotal = $649,138 )
2023	2023	BAYLOR COLLEGE OF MEDICINE	1 BAYLOR PLZ	HOUSTON	TX	77030	HARRIS	USA	Cancer Biology Research	000	1	12/30/2022	NEW	$649,138
														Subtotal = $649,138

Grand Total All Awards = $2,404,391

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Elucidating the role of gut microbiota in colitis-associated colorectal cancer

Award Number: R01CA276173

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 01/01/2023

PERIOD OF PERFORMANCE END DATE: 12/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer